Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NK cell-enriched donor lymphocyte infusion + DUK-CPG-001
- Development stage
- Unknown
- Lead developer
- Duke University
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Cell Therapies, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
NK cell-enriched donor lymphocyte infusion (NK-DLI) + DUK-CPG-001 is a combination investigational therapy used in the context of allogeneic stem cell transplantation for hematologic malignancies. NK-DLI refers to infusions of donor-derived, natural killer (NK) cells that are enriched and administered to patients post-transplant to enhance graft-versus-leukemia effects. DUK-CPG-001 is a synthetic CpG-rich oligonucleotide that acts as an agonist of Toll-like receptor 9 (TLR9), stimulating innate immune responses by activating intracellular TLR9 and promoting immunopotentiation[1][2][3]. The combination aims to improve anti-tumor immunity by both direct cytotoxicity from NK cells and immune activation via TLR9 stimulation. This approach has been studied in phase 2 clinical trials primarily at Duke University for patients with myeloid or lymphoid malignancies following reduced intensity or non-myeloablative allogeneic stem cell transplantation[2][5].
- Other names
- natural killer cell-enriched donor lymphocyte infusion + TLR9 agonist DUK-CPG-001
02
Targets
TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on NK cell-enriched donor lymphocyte infusion + DUK-CPG-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NK cell-enriched donor lymphocyte infusion + DUK-CPG-001.